J. Noeldeke

Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program

Russell H. Tobe, Christopher H. Chatham, E. Hollander, 2022, Molecular Autism.

Prospective Age‐Matching in Elderly Kidney Transplant Recipients—A 5‐Year Analysis of the Eurotransplant Senior Program

K. Lopau, R. Margreiter, G. Persijn, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

398: Premature termination of a prospective, open label, randomized, multicenter study of sirolimus to replace calcineurin inhibitors (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation

R. Starling, J. Kobashigawa, N. Banner, 2007 .

Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1.

C. Rommel, A. Aitken, K. Moelling, 1996, Oncogene.

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

J. Hipp, M. Rafii, P. Fontoura, 2022, Journal of neurodevelopmental disorders.

Adaptive behavior in adolescents and adults with Down syndrome: Results from a 6‐month longitudinal study

Sarah J. Hart, L. Squassante, G. Spiridigliozzi, 2018, American journal of medical genetics. Part A.

Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger’s Versus Healthy Controls: A Cross-Sectional Analysis

E. Hollander, F. Shic, J. McCracken, 2020, Journal of Autism and Developmental Disorders.

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder

E. Hollander, F. Shic, J. McCracken, 2017, Neuropsychopharmacology.

In Search of Biomarkers for Autism Spectrum Disorder

E. Hollander, F. Shic, J. McCracken, 2018, Autism research : official journal of the International Society for Autism Research.

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder

E. Hollander, F. Shic, J. McCracken, 2016, Neuropsychopharmacology.

RG1662, a Selective GABAA α5 Receptor Negative Allosteric Modulator, Increases Gamma Power in Young Adults with Down Syndrome. (P6.273)

L. Squassante, S. Nave, F. Knoflach, 2015 .

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

J. Hipp, M. Rafii, P. Fontoura, 2022, Journal of Neurodevelopmental Disorders.